BioCentury
ARTICLE | Company News

Mira Dx, Yale University deal

March 7, 2011 8:00 AM UTC

Mira licensed IP covering the rs8176318 microRNA disrupting variant of breast cancer 1 early onset (BRCA1) from the university. The company plans to use the variant in its triple-negative breast canc...